605 lines
No EOL
165 KiB
HTML
605 lines
No EOL
165 KiB
HTML
<?xml version="1.0" encoding="utf-8"?>
|
|
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
|
|
|
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
|
<!-- AppResources meta begin -->
|
|
<meta name="paf-app-resources" content="" />
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- AppResources meta end -->
|
|
|
|
<!-- TemplateResources meta begin -->
|
|
<meta name="paf_template" content="" />
|
|
|
|
<!-- TemplateResources meta end -->
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK65870" /><meta name="ncbi_domain" content="pdqcis" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK65870.4/" /><meta name="ncbi_pagename" content="Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
|
|
<!-- Logger end -->
|
|
|
|
<title>Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf</title>
|
|
|
|
<!-- AppResources external_resources begin -->
|
|
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
|
|
|
<!-- AppResources external_resources end -->
|
|
|
|
<!-- Page meta begin -->
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="PDQ Cancer Information Summaries [Internet]" /><meta name="citation_title" content="Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)" /><meta name="citation_publisher" content="National Cancer Institute (US)" /><meta name="citation_date" content="2019/12/13" /><meta name="citation_author" content="PDQ Adult Treatment Editorial Board" /><meta name="citation_pmid" content="26389309" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK65870/" /><meta name="citation_keywords" content="islet cell carcinoma" /><meta name="citation_keywords" content="islet cell carcinoma" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Cancer Institute (US)" /><meta name="DC.Contributor" content="PDQ Adult Treatment Editorial Board" /><meta name="DC.Date" content="2019/12/13" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK65870/" /><meta name="description" content="Pancreatic neuroendocrine tumors (islet cell tumors) treatment includes surgery with curative intent and surgery for metastatic disease. Hormone therapy, chemotherapy and targeted therapy are sometimes used. Get detailed information on the treatment of this disease in this clinician summary." /><meta name="og:title" content="Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)" /><meta name="og:type" content="book" /><meta name="og:description" content="Pancreatic neuroendocrine tumors (islet cell tumors) treatment includes surgery with curative intent and surgery for metastatic disease. Hormone therapy, chemotherapy and targeted therapy are sometimes used. Get detailed information on the treatment of this disease in this clinician summary." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK65870/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-pdqcis-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/pdqcis/CDR0000062794/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK65870/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script><meta name="book-collection" content="NONE" />
|
|
|
|
<!-- Page meta end -->
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8BF5F67C953BE10000000000670050.m_13" />
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/4207974/4206132/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
|
<body class="book-part">
|
|
<div class="grid">
|
|
<div class="col twelve_col nomargin shadow">
|
|
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
|
<div class="sysmessages">
|
|
<noscript>
|
|
<p class="nojs">
|
|
<strong>Warning:</strong>
|
|
The NCBI web site requires JavaScript to function.
|
|
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
|
</p>
|
|
</noscript>
|
|
</div>
|
|
<!--/.sysmessage-->
|
|
<div class="wrap">
|
|
<div class="page">
|
|
<div class="top">
|
|
<div id="universal_header">
|
|
<section class="usa-banner">
|
|
<div class="usa-accordion">
|
|
<header class="usa-banner-header">
|
|
<div class="usa-grid usa-banner-inner">
|
|
<img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
|
|
<p>An official website of the United States government</p>
|
|
<button class="non-usa-accordion-button usa-banner-button" aria-expanded="false" aria-controls="gov-banner-top" type="button">
|
|
<span class="usa-banner-button-text">Here's how you know</span>
|
|
</button>
|
|
</div>
|
|
</header>
|
|
<div class="usa-banner-content usa-grid usa-accordion-content" id="gov-banner-top" aria-hidden="true">
|
|
<div class="usa-banner-guidance-gov usa-width-one-half">
|
|
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg" alt="Dot gov" />
|
|
<div class="usa-media_block-body">
|
|
<p>
|
|
<strong>The .gov means it's official.</strong>
|
|
<br />
|
|
Federal government websites often end in .gov or .mil. Before
|
|
sharing sensitive information, make sure you're on a federal
|
|
government site.
|
|
</p>
|
|
</div>
|
|
</div>
|
|
<div class="usa-banner-guidance-ssl usa-width-one-half">
|
|
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg" alt="Https" />
|
|
<div class="usa-media_block-body">
|
|
<p>
|
|
<strong>The site is secure.</strong>
|
|
<br />
|
|
The <strong>https://</strong> ensures that you are connecting to the
|
|
official website and that any information you provide is encrypted
|
|
and transmitted securely.
|
|
</p>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
<div class="usa-overlay"></div>
|
|
<header class="ncbi-header" role="banner" data-section="Header">
|
|
|
|
<div class="usa-grid">
|
|
<div class="usa-width-one-whole">
|
|
|
|
<div class="ncbi-header__logo">
|
|
<a href="/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
|
|
<img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
|
|
</a>
|
|
</div>
|
|
|
|
<div class="ncbi-header__account">
|
|
<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
|
|
<button id="account_info" class="header-button" style="display:none" aria-controls="account_popup" type="button">
|
|
<span class="fa fa-user" aria-hidden="true">
|
|
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="20px" height="20px">
|
|
<g style="fill: #fff">
|
|
<ellipse cx="12" cy="8" rx="5" ry="6"></ellipse>
|
|
<path d="M21.8,19.1c-0.9-1.8-2.6-3.3-4.8-4.2c-0.6-0.2-1.3-0.2-1.8,0.1c-1,0.6-2,0.9-3.2,0.9s-2.2-0.3-3.2-0.9 C8.3,14.8,7.6,14.7,7,15c-2.2,0.9-3.9,2.4-4.8,4.2C1.5,20.5,2.6,22,4.1,22h15.8C21.4,22,22.5,20.5,21.8,19.1z"></path>
|
|
</g>
|
|
</svg>
|
|
</span>
|
|
<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
|
|
<span class="sr-only">Show account info</span>
|
|
</button>
|
|
</div>
|
|
|
|
<div class="ncbi-popup-anchor">
|
|
<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
|
|
<div class="ncbi-popup-head">
|
|
<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu" type="button">
|
|
<span class="fa fa-times">
|
|
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" height="24px">
|
|
<path d="M38 12.83l-2.83-2.83-11.17 11.17-11.17-11.17-2.83 2.83 11.17 11.17-11.17 11.17 2.83 2.83 11.17-11.17 11.17 11.17 2.83-2.83-11.17-11.17z"></path>
|
|
</svg>
|
|
</span>
|
|
<span class="usa-sr-only">Close</span></button>
|
|
<h4>Account</h4>
|
|
</div>
|
|
<div class="account-user-info">
|
|
Logged in as:<br />
|
|
<b><span class="username" id="uname_long">username</span></b>
|
|
</div>
|
|
<div class="account-links">
|
|
<ul class="usa-unstyled-list">
|
|
<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
|
|
<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
|
|
<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
|
|
<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
|
|
</ul>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
</div>
|
|
</div>
|
|
</header>
|
|
<div role="navigation" aria-label="access keys">
|
|
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
|
|
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
|
|
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
|
|
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
|
|
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
|
|
</div>
|
|
<section data-section="Alerts">
|
|
<div class="ncbi-alerts-placeholder"></div>
|
|
</section>
|
|
</div>
|
|
<div class="header">
|
|
<div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
|
|
<div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" data-ac_dict="bookshelf-search">Books</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="clinvar" class="last">ClinVar</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
|
|
<a href="/books/browse/">Browse Titles</a>
|
|
</li><li>
|
|
<a href="/books/advanced/">Advanced</a>
|
|
</li><li class="help">
|
|
<a href="/books/NBK3833/">Help</a>
|
|
</li><li class="disclaimer">
|
|
<a target="_blank" data-ga-category="literature_resources" data-ga-action="link_click" data-ga-label="disclaimer_link" href="https://www.ncbi.nlm.nih.gov/books/about/disclaimer/">Disclaimer</a>
|
|
</li></ul></div>
|
|
</div>
|
|
|
|
|
|
|
|
<!--<component id="Page" label="headcontent"/>-->
|
|
|
|
</div>
|
|
<div class="content">
|
|
<!-- site messages -->
|
|
<!-- Custom content 1 -->
|
|
<div class="col1">
|
|
|
|
</div>
|
|
|
|
<div class="container">
|
|
<div id="maincontent" class="content eight_col col">
|
|
<!-- Custom content in the left column above book nav -->
|
|
<div class="col2">
|
|
|
|
</div>
|
|
|
|
<!-- Book content -->
|
|
|
|
|
|
<!-- Custom content between navigation and content -->
|
|
<div class="col3">
|
|
|
|
</div>
|
|
|
|
<div class="document">
|
|
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="Table of Contents Page" href="/books/n/pdqcis/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-pdqcis-lrg.png" alt="Cover of PDQ Cancer Information Summaries" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>PDQ Cancer Information Summaries [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK65870_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK65870_dtls__"><div>Bethesda (MD): <a href="http://www.cancer.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Cancer Institute (US)</a>; 2002-.</div></div><div class="half_rhythm"></div><div class="bk_noprnt"><form method="get" action="/books/n/pdqcis/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div></div></div></div>
|
|
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK65870_"><span class="title" itemprop="name">Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)</span></h1><div class="subtitle whole_rhythm">Health Professional Version</div><p class="contrib-group"><span itemprop="author">PDQ Adult Treatment Editorial Board</span>.</p><p class="small">Published online: December 13, 2019.</p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="_abs_rndgid_" itemprop="description"><p id="CDR0000062794__270">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of pancreatic neuroendocrine tumors (islet cell tumors). It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.</p><p id="CDR0000062794__271">This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p></div><div id="CDR0000062794__1"><h2 id="_CDR0000062794__1_">General Information About Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)</h2><div id="CDR0000062794__263"><h3>Incidence and Mortality</h3><p id="CDR0000062794__264">Pancreatic neuroendocrine tumors (NETs) are uncommon cancers with about 1,000 new cases
|
|
per year in the United States.[<a class="bk_pop" href="#CDR0000062794_rl_1_1">1</a>] They account for less than 2% of pancreatic malignancies and overall have a better prognosis than the more common pancreatic exocrine tumors.[<a class="bk_pop" href="#CDR0000062794_rl_1_1">1</a>,<a class="bk_pop" href="#CDR0000062794_rl_1_2">2</a>] </p></div><div id="CDR0000062794__265"><h3>Pathogenesis</h3><p id="CDR0000062794__2">Tumors of the endocrine pancreas are a collection of tumor cell types collectively referred to as pancreatic NETs. These tumors originate in islet cells. Although they may be similar or identical in histologic appearance to carcinoid tumors of the gastrointestinal tract, differences in their underlying biology and likely differences in response to therapeutic agents suggest that they should be treated and investigated as a distinct entity.[<a class="bk_pop" href="#CDR0000062794_rl_1_3">3</a>] </p><p id="CDR0000062794__150">Most pancreatic NETs are sporadic, but some occur as part of the autosomal dominant multiple endocrine neoplasia type 1 (MEN1) inherited syndrome consisting of tumors of the anterior pituitary, parathyroid, and endocrine pancreas glands, which results from the inactivation of the tumor suppressor gene <i>Menin</i> located on chromosome 11q13.[<a class="bk_pop" href="#CDR0000062794_rl_1_4">4</a>] When part of the MEN1 syndrome, there may be multiple pancreatic tumors.</p><p id="CDR0000062794__151">Islet tumors may
|
|
either be functional (produce one or more active hormones) or nonfunctional.[<a class="bk_pop" href="#CDR0000062794_rl_1_4">4</a>] The functional tumors, which usually present with symptoms of hormone hypersecretion, include: </p><ul id="CDR0000062794__152"><li class="half_rhythm"><div>Gastrinoma.</div></li><li class="half_rhythm"><div>Insulinoma.</div></li><li class="half_rhythm"><div>Glucagonoma.</div></li><li class="half_rhythm"><div>Somatostatinoma.</div></li><li class="half_rhythm"><div>VIPoma.</div></li></ul></div><div id="CDR0000062794__266"><h3>Prognostic Factors</h3><p id="CDR0000062794__153">Most islet cell cancers are functional, but about 15% are nonfunctional, with presentations similar to the far more common exocrine adenocarcinomas of the pancreas.[<a class="bk_pop" href="#CDR0000062794_rl_1_5">5</a>-<a class="bk_pop" href="#CDR0000062794_rl_1_7">7</a>] Because of the presence of several cell types in the pancreatic islets (alpha, beta, delta, A, B, C, D, E, F), the term islet cell tumors refers to at
|
|
least five distinct cancers that, when functional, produce unique metabolic
|
|
and clinical characteristics. The clinical manifestations in functional
|
|
tumors may result from the distinctive metabolic effects of the polypeptide(s) secreted by the
|
|
cancer cells rather than from tumor bulk or metastatic disease.
|
|
Functional tumors may even be too small to be detected by conventional
|
|
imaging techniques.
|
|
</p><p id="CDR0000062794__258">Nonfunctional tumors tend to present at later clinical stages with symptoms attributable to mass effect or metastases.[<a class="bk_pop" href="#CDR0000062794_rl_1_4">4</a>] Although nonfunctional tumors do not produce specific clinical syndromes, they may secrete inactive amine and peptide products such as the following: </p><ul id="CDR0000062794__222"><li class="half_rhythm"><div>Neurotensin.</div></li><li class="half_rhythm"><div>Alpha-subunit of human chorionic gonadotropin (alpha-hCG).</div></li><li class="half_rhythm"><div>Neuron-specific enolase.</div></li><li class="half_rhythm"><div>Pancreatic polypeptide.</div></li><li class="half_rhythm"><div>Chromogranin A.</div></li></ul></div><div id="CDR0000062794__267"><h3>Diagnostics</h3><p id="CDR0000062794__3">The frequent long delays between initial symptoms and diagnosis and the varied
|
|
effects of the polypeptides secreted often necessitate involvement of multiple
|
|
surgical and medical subspecialties. Surgery is the only curative
|
|
modality. Surgery is often used even in the setting of metastatic disease to alleviate the symptoms of hormonal hypersecretion.[<a class="bk_pop" href="#CDR0000062794_rl_1_4">4</a>] Effective
|
|
palliation may be achieved because of the slow-growing nature of the majority
|
|
of these tumors and the potential use of antihormonal pharmacologic therapy
|
|
(e.g., cimetidine in the ulcer-producing Zollinger-Ellison syndrome).
|
|
In patients with indolent, slow-growing
|
|
metastatic islet cell tumors, the best therapy may be careful observation,
|
|
and no treatment until palliation is required. In patients with MEN1 in which
|
|
85% have pancreatic islet cell tumors, 90% have hyperparathyroidism, and 65%
|
|
have pituitary tumors, and they are less likely to be cured by pancreatic resection than
|
|
are patients with sporadic islet cell tumors. With the exception of pain
|
|
relief from bone metastases, radiation therapy has a limited role in this
|
|
disease.
|
|
</p><p id="CDR0000062794__155">Tumor localization and staging studies include imaging with computed tomography (CT) with or without magnetic resonance imaging (MRI), and endoscopic ultrasound. In addition, somatostatin-receptor scintigraphy and single-photon emission CT may be useful adjuncts. However, somatostatin-receptor scintigraphy has diminished utility in localizing insulinomas versus other pancreatic NETs, since insulinomas often have a low density of somatostatin receptors.[<a class="bk_pop" href="#CDR0000062794_rl_1_4">4</a>] If the noninvasive tests do not reveal a tumor, but clinical suspicion remains high, more invasive and technically demanding tests, such as selective arteriography or selective arterial stimulation (with a secretagogue specific for the suspected tumor type), may be useful.[<a class="bk_pop" href="#CDR0000062794_rl_1_7">7</a>]</p><p id="CDR0000062794__243">Some of the tumor types have unique characteristics that require specific approaches in their diagnosis and initial evaluation.</p><div id="CDR0000062794__244"><h4>Gastrinoma</h4><p id="CDR0000062794__245">Diagnosis is dependent on elevated serum gastrin and elevated gastric acid
|
|
levels. Provocative testing with calcium and secretin shows considerable
|
|
overlap, and the value of these tests is limited. Zollinger-Ellison syndrome
|
|
is a condition of unrelenting peptic ulcer disease, diarrhea, and gastric
|
|
hyperacidity, associated with a gastrin-producing tumor. (Refer to the <a href="/books/n/pdqcis/CDR0000062736/#CDR0000062736__119">Diarrhea</a> section in the PDQ summary on <a href="/books/n/pdqcis/CDR0000062736/">Gastrointestinal Complications</a> for more information.) It accounts for less
|
|
than 1% of all peptic ulcer disease. About 15% to 35% of gastrinomas are associated with the MEN1 syndrome and up to 50% are malignant. Up to 33% of gastrinomas have liver metastases.[<a class="bk_pop" href="#CDR0000062794_rl_1_4">4</a>]</p><h5><span class="title">Diagnostic tests:
|
|
</span></h5><ol id="CDR0000062794__246"><li class="half_rhythm"><div>BAO:MAO ≥ = 0.6 (basal acid output : maximal acid output).
|
|
</div></li><li class="half_rhythm"><div>Overnight AO ≥ = 100 mmol.</div></li><li class="half_rhythm"><div>BAO ≥ = 10 mmol/hr.</div></li><li class="half_rhythm"><div> Serum gastrin 10x normal or >500 pg/mL (the
|
|
accuracy of gastrin assays may vary widely).
|
|
</div></li><li class="half_rhythm"><div>Secretin test: 1 unit/kg intravenous rapid injection: Positive = 100% increase
|
|
in gastrin within 10 minutes; 2 units/kg: Positive = 100% increase
|
|
over baseline.
|
|
</div></li><li class="half_rhythm"><div>Elevated hCG levels.</div></li></ol></div><div id="CDR0000062794__247"><h4>Insulinoma</h4><p id="CDR0000062794__248">Insulinomas are far more likely to be benign than malignant. Only 10% are
|
|
multiple, and only 10% are malignant. About 5% to 8% are associated with MEN1 syndrome.[<a class="bk_pop" href="#CDR0000062794_rl_1_4">4</a>] The
|
|
clinical manifestations are those of hypoglycemia, which results from
|
|
inappropriate secretion of insulin by the tumor. Fasting hypoglycemia (<40 mg/dL) associated with
|
|
an elevated insulin level (in the absence of exogenous administration of
|
|
insulin) is pathognomonic. Measurement of plasma proinsulin may be helpful for
|
|
diagnosing insulin-secreting carcinomas. These tumors are usually slow-growing tumors
|
|
and, when localized to the pancreas or regional lymph nodes, can be cured with
|
|
pancreatic resection.</p><p id="CDR0000062794__249">The approach to management depends on carefully
|
|
performed preoperative localization studies and the findings at exploratory
|
|
laparotomy. In a retrospective case series of 30 patients with 32 pancreatic insulinomas, the combination of preoperative dual-phase thin-section multidetector CT and endoscopic sonography correctly identified and localized all of the tumors.[<a class="bk_pop" href="#CDR0000062794_rl_1_8">8</a>] These tests, with or without MRI, have replaced older, more invasive, and technically challenging tests, such as percutaneous transhepatic portal venous sampling and arterial stimulation with venous sampling except for unusual circumstances in which the imaging tests are unsuccessful.[<a class="bk_pop" href="#CDR0000062794_rl_1_4">4</a>,<a class="bk_pop" href="#CDR0000062794_rl_1_9">9</a>]</p></div><div id="CDR0000062794__250"><h4>Glucagonoma</h4><p id="CDR0000062794__251">Glucagonoma is the third most common endocrine-secreting islet cell tumor. About 75% of glucagonomas are malignant.[<a class="bk_pop" href="#CDR0000062794_rl_1_4">4</a>] Necrolytic migratory erythema, hyperglycemia,
|
|
and venous thrombosis comprise a virtually diagnostic triad. A serum glucagon level greater than 1,000 pg/mL confirms the diagnosis. These tumors tend to be large and easily visible on CT scan. Somatostatin receptor scintigraphy scanning may be a useful adjunct in detecting metastases.</p></div><div id="CDR0000062794__252"><h4>Miscellaneous islet cell tumors</h4><p id="CDR0000062794__253">These tumors are rare but have defined clinical syndromes associated with specific production of polypeptide hormone production by islet cell tumors. Because of their rarity and similar approaches to management, they are grouped in the section on treatment. Miscellaneous tumors include the following: </p><ul id="CDR0000062794__254"><li class="half_rhythm"><div class="half_rhythm">VIPoma (Verner-Morrison syndrome) is characterized by watery diarrhea,
|
|
hypokalemia, and achlorhydria.</div><div class="half_rhythm">A serum vasoactive intestinal peptide (VIP) greater than 200 pg/mL is diagnostic.[<a class="bk_pop" href="#CDR0000062794_rl_1_4">4</a>] These tumors can generally be easily localized by CT scan. Somatostatin receptor scintigraphy scanning may be a useful adjunct in detecting metastases.</div></li><li class="half_rhythm"><div class="half_rhythm">Somatostatinoma.
|
|
</div><div class="half_rhythm">These tumors are particularly rare. They often present with diarrhea, steatorrhea, diabetes, and/or gallstones. Decreased pancreatic secretion of enzymes and bicarbonate accounts for the diarrhea and steatorrhea. Somatostatin-mediated inhibition of cholecystokinin leads to gallstone formation. Somatostatin also inhibits insulin, producing hyperglycemia. The diagnosis is made by a fasting serum somatostatin level greater than 100 pg/mL. CT scan, MRI, and endoscopic ultrasound can usually help localize and stage the tumor. Most of these tumors are malignant and have metastases at diagnosis.</div></li></ul></div></div><div id="CDR0000062794__225"><h3>Related Summaries</h3><ul id="CDR0000062794__226"><li class="half_rhythm"><div><a href="/books/n/pdqcis/CDR0000062893/">Gastrointestinal Carcinoid Tumors Treatment (Adult)</a></div></li><li class="half_rhythm"><div><a href="/books/n/pdqcis/CDR0000062890/">Genetics of Endocrine and Neuroendocrine Neoplasias</a></div></li><li class="half_rhythm"><div><a href="/books/n/pdqcis/CDR0000062951/">Pancreatic Cancer Treatment (Adult)</a></div></li></ul></div><div id="CDR0000062794_rl_1"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062794_rl_1_1">Ries LAG, Young JL, Keel GE, et al., eds.: SEER Survival Monograph: Cancer Survival Among Adults: U. S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute, 2007. NIH Pub. No. 07-6215.</div></li><li><div class="bk_ref" id="CDR0000062794_rl_1_2">Neuroendocrine tumors of the pancreas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp. 407–19.</div></li><li><div class="bk_ref" id="CDR0000062794_rl_1_3">Kulke MH, Siu LL, Tepper JE, et al.: Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29 (7): 934-43, 2011. [<a href="/pmc/articles/PMC3068065/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3068065</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21263089" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21263089</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_1_4">Davies K, Conlon KC: Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep 11 (2): 119-27, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19281699" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19281699</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_1_5">Hochwald SN, Zee S, Conlon KC, et al.: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20 (11): 2633-42, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12039924" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12039924</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_1_6">O'Grady HL, Conlon KC: Pancreatic neuroendocrine tumours. Eur J Surg Oncol 34 (3): 324-32, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/17967523" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17967523</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_1_7">King CM, Reznek RH, Dacie JE, et al.: Imaging islet cell tumours. Clin Radiol 49 (5): 295-303, 1994. [<a href="https://pubmed.ncbi.nlm.nih.gov/8013189" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8013189</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_1_8">Gouya H, Vignaux O, Augui J, et al.: CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 181 (4): 987-92, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/14500214" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14500214</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_1_9">Nikfarjam M, Warshaw AL, Axelrod L, et al.: Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg 247 (1): 165-72, 2008. [<a href="/pmc/articles/PMC3806046/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3806046</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18156937" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18156937</span></a>]</div></li></ol></div></div><div id="CDR0000062794__4"><h2 id="_CDR0000062794__4_">Cellular Classification of Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)</h2><div id="CDR0000062794__2024" class="table"><h3><span class="title">Table 1. Endocrine Tumors of the Pancreas</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65870.4/table/CDR0000062794__2024/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000062794__2024_lrgtbl__"><table class="no_margin"><thead><tr><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Islet Cells</th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Secreted Active Agent</th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Tumor and Syndrome</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Alpha</td><td colspan="1" rowspan="1" style="vertical-align:top;">Glucagon</td><td colspan="1" rowspan="1" style="vertical-align:top;">Glucagonoma (diabetes, dermatitis)</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Beta</td><td colspan="1" rowspan="1" style="vertical-align:top;">Insulin</td><td colspan="1" rowspan="1" style="vertical-align:top;">Insulinoma (hypoglycemia)</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Delta</td><td colspan="1" rowspan="1" style="vertical-align:top;">Somatostatin</td><td colspan="1" rowspan="1" style="vertical-align:top;">Somatostatinoma (mild diabetes); diarrhea/steatorrhea; gallstones</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">D</td><td colspan="1" rowspan="1" style="vertical-align:top;">Gastrin</td><td colspan="1" rowspan="1" style="vertical-align:top;">Gastrinoma (peptic ulcer disease)</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">A→D</td><td colspan="1" rowspan="1" style="vertical-align:top;">VIP and/or other undefined mediators</td><td colspan="1" rowspan="1" style="vertical-align:top;">WDHA</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;"></td><td colspan="1" rowspan="1" style="vertical-align:top;">5-HT</td><td colspan="1" rowspan="1" style="vertical-align:top;">Carcinoid</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;"></td><td colspan="1" rowspan="1" style="vertical-align:top;">ACTH</td><td colspan="1" rowspan="1" style="vertical-align:top;">Cushing disease</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;"></td><td colspan="1" rowspan="1" style="vertical-align:top;">MSH</td><td colspan="1" rowspan="1" style="vertical-align:top;">Hyperpigmentation</td></tr><tr><td colspan="1" rowspan="1" style="text-align:center;vertical-align:top;"><b>Interacinar Cells</b></td><td colspan="1" rowspan="1" style="text-align:center;vertical-align:top;"><b>Secreted Active Agent</b></td><td colspan="1" rowspan="1" style="text-align:center;vertical-align:top;"><b>Tumor and Syndrome</b></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">F</td><td colspan="1" rowspan="1" style="vertical-align:top;">Pancreatic polypeptide</td><td colspan="1" rowspan="1" style="vertical-align:top;">Multiple hormonal syndromes</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">EC</td><td colspan="1" rowspan="1" style="vertical-align:top;">5-HT</td><td colspan="1" rowspan="1" style="vertical-align:top;">Carcinoid</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">5-HT = serotonin; ACTH = adrenocorticotropin hormone; MSH = melanocyte-stimulating hormone; VIP = vasoactive intestinal peptide; WDHA = watery diarrhea, hypokalemia, and achlorhydria.</p></div></dd></dl></div></div></div></div><div id="CDR0000062794__199"><h2 id="_CDR0000062794__199_">Stage Information for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)</h2><div id="CDR0000062794__201"><h3>American Joint Committee on Cancer (AJCC) Stage Groupings and TNM Definitions</h3><p id="CDR0000062794__259">The AJCC has designated staging by TNM
|
|
(tumor, node, metastasis) classification to define pancreatic neuroendocrine tumors (islet cell tumors).[<a class="bk_pop" href="#CDR0000062794_rl_199_1">1</a>]</p><div id="CDR0000062794__2026" class="table"><h3><span class="title">Table 2. Definitions for TNM Stage I<sup>a</sup></span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65870.4/table/CDR0000062794__2026/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000062794__2026_lrgtbl__"><table class="no_margin"><thead><tr><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Stage</th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">TNM</th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Definition</th></tr></thead><tbody><tr><td colspan="1" rowspan="3" style="vertical-align:top;">I</td><td colspan="1" rowspan="3" style="vertical-align:top;">T1, N0, M0</td><td colspan="1" rowspan="1" style="vertical-align:top;">T1 = Tumor limited to the pancreas,<sup>b</sup> <2 cm.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N0 = No regional lymph node involvement.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M0 = No distant metastasis. </td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">T = primary tumor; N = regional lymph node; M = distant metastasis.</p></div></dd><dt></dt><dd><div><p class="no_margin"><sup>a</sup>Reprinted with permission from AJCC: Neuroendocrine Tumors of the Pancreas. In: Amin MB, Edge SB, Greene FL, et al., eds.: <i>AJCC Cancer Staging Manual</i>. 8th ed. New York, NY: Springer, 2017, pp. 407–19.</p></div></dd><dt></dt><dd><div><p class="no_margin"><sup>b</sup>The explanation for superscript b is at the end of <a class="figpopup" href="/books/NBK65870.4/table/CDR0000062794__2029/?report=objectonly" target="object" rid-figpopup="figCDR00000627942029" rid-ob="figobCDR00000627942029">Table 5</a>. </p></div></dd></dl></div></div></div><div id="CDR0000062794__2027" class="table"><h3><span class="title">Table 3. Definitions for TNM Stage II<sup>a</sup></span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65870.4/table/CDR0000062794__2027/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000062794__2027_lrgtbl__"><table class="no_margin"><thead><tr><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Stage</th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">TNM</th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Definition</th></tr></thead><tbody><tr><td colspan="1" rowspan="6" style="vertical-align:top;">II</td><td colspan="1" rowspan="3" style="vertical-align:top;">T2, N0, M0</td><td colspan="1" rowspan="1" style="vertical-align:top;">T2 = Tumor limited to the pancreas,<sup>b</sup> 2–4 cm.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N0 = No regional lymph node involvement.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M0 = No distant metastasis. </td></tr><tr><td colspan="1" rowspan="3" style="vertical-align:top;">T3, N0, M0</td><td colspan="1" rowspan="1" style="vertical-align:top;">T3 = Tumor limited to the pancreas,<sup>b</sup> >4 cm; <i>or</i> tumor invading the duodenum or common bile duct.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N0 = No regional lymph node involvement.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M0 = No distant metastasis. </td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">T = primary tumor; N = regional lymph node; M = distant metastasis.</p></div></dd><dt></dt><dd><div><p class="no_margin"><sup>a</sup>Reprinted with permission from AJCC: Neuroendocrine Tumors of the Pancreas. In: Amin MB, Edge SB, Greene FL, et al., eds.: <i>AJCC Cancer Staging Manual</i>. 8th ed. New York, NY: Springer, 2017, pp. 407–19.</p></div></dd><dt></dt><dd><div><p class="no_margin"><sup>b</sup>The explanation for superscript b is at the end of <a class="figpopup" href="/books/NBK65870.4/table/CDR0000062794__2029/?report=objectonly" target="object" rid-figpopup="figCDR00000627942029" rid-ob="figobCDR00000627942029">Table 5</a>. </p></div></dd></dl></div></div></div><div id="CDR0000062794__2028" class="table"><h3><span class="title">Table 4. Definitions for TNM Stage III<sup>a</sup></span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65870.4/table/CDR0000062794__2028/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000062794__2028_lrgtbl__"><table class="no_margin"><thead><tr><th colspan="1" rowspan="1" style="vertical-align:top;">Stage </th><th colspan="1" rowspan="1" style="vertical-align:top;">TNM</th><th colspan="1" rowspan="1" style="vertical-align:top;">Definition</th></tr></thead><tbody><tr><td colspan="1" rowspan="10" style="vertical-align:top;">III</td><td colspan="1" rowspan="3" style="vertical-align:top;">T4, N0, M0</td><td colspan="1" rowspan="1" style="vertical-align:top;">T4 = Tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery).</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N0 = No regional lymph node involvement.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M0 = No distant metastasis.</td></tr><tr><td colspan="1" rowspan="7" style="vertical-align:top;">Any T, N1, M0</td><td colspan="1" rowspan="1" style="vertical-align:top;">TX = Tumor cannot be assessed.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">T1 = Tumor limited to the pancreas,<sup>b</sup> <2 cm.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">T2 = Tumor limited to the pancreas,<sup>b</sup> 2–4 cm.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">T3 = Tumor limited to the pancreas,<sup>b</sup> >4 cm; <i>or</i> tumor invading the duodenum or common bile duct.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">T4 = Tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery).</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N1 = Regional lymph node involvement.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M0 = No distant metastasis.</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">T = primary tumor; N = regional lymph node; M = distant metastasis.</p></div></dd><dt></dt><dd><div><p class="no_margin"><sup>a</sup>Reprinted with permission from AJCC: Neuroendocrine Tumors of the Pancreas. In: Amin MB, Edge SB, Greene FL, et al., eds.: <i>AJCC Cancer Staging Manual</i>. 8th ed. New York, NY: Springer, 2017, pp. 407–19.</p></div></dd><dt></dt><dd><div><p class="no_margin"><sup>b</sup>The explanation for superscript b is at the end of <a class="figpopup" href="/books/NBK65870.4/table/CDR0000062794__2029/?report=objectonly" target="object" rid-figpopup="figCDR00000627942029" rid-ob="figobCDR00000627942029">Table 5</a>. </p></div></dd></dl></div></div></div><div id="CDR0000062794__2029" class="table"><h3><span class="title">Table 5. Definitions for TNM Stage IV<sup>a</sup></span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65870.4/table/CDR0000062794__2029/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000062794__2029_lrgtbl__"><table class="no_margin"><thead><tr><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Stage </th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">TNM</th><th colspan="1" rowspan="1" style="text-align:center;vertical-align:top;">Definition</th></tr></thead><tbody><tr><td colspan="1" rowspan="12" style="vertical-align:top;">IV</td><td colspan="1" rowspan="12" style="vertical-align:top;">Any T, Any N, M1</td><td colspan="1" rowspan="1" style="vertical-align:top;">TX = Tumor cannot be assessed.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">T1 = Tumor limited to the pancreas,<sup>b</sup> <2 cm.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">T2 = Tumor limited to the pancreas,<sup>b</sup> 2–4 cm.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">T3 = Tumor limited to the pancreas,<sup>b</sup> >4 cm; <i>or</i> tumor invading the duodenum or common bile duct.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">T4 = Tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery).</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">NX = Regional lymph nodes cannot be assessed.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N0 = No regional lymph node involvement.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N1 = Regional lymph node involvement.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">M1 = Distant metastases.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–M1a = Metastasis confined to liver.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–M1b = Metastases in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone).</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">–M1c = Both hepatic and extrahepatic metastases.</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">T = primary tumor; N = regional lymph node; M = distant metastasis.</p></div></dd><dt></dt><dd><div><p class="no_margin"><sup>a</sup>Reprinted with permission from AJCC: Neuroendocrine Tumors of the Pancreas. In: Amin MB, Edge SB, Greene FL, et al., eds.: <i>AJCC Cancer Staging Manual</i>. 8th ed. New York, NY: Springer, 2017, pp. 407–19.</p></div></dd><dt></dt><dd><div><p class="no_margin"><sup>b</sup><i>Limited to the pancreas</i> means there is no invasion of adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery). Extension of tumor into peripancreatic adipose tissue is NOT a basis for staging. <i>Note</i>: Multiple tumors should be designated as such (the largest tumor should be used to assign T category): if the number of tumors is known, use T(#); e.g., pT3(4) N0 M0; if the number of tumors is unavailable or too numerous, use the <i>m</i> suffix, T(m); e.g., pT3(m) N0 M0.</p></div></dd></dl></div></div></div></div><div id="CDR0000062794_rl_199"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062794_rl_199_1">Neuroendocrine tumors of the pancreas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp. 407–19.</div></li></ol></div></div><div id="CDR0000062794__162"><h2 id="_CDR0000062794__162_">Treatment Option Overview</h2><div id="CDR0000062794__227"><h3>Localized Disease</h3><p id="CDR0000062794__228">If technically and medically feasible, primary management of endocrine tumors of the pancreas involves surgical resection with curative intent. Given the rare nature of these tumors, surgical approaches are based on case series and expert opinion rather than randomized controlled trials.[<a class="bk_pop" href="#CDR0000062794_rl_162_1">1</a>] The surgical options listed below are based on retrospective series from single reporting centers.[<a class="bk_pop" href="#CDR0000062794_rl_162_2">2</a>-<a class="bk_pop" href="#CDR0000062794_rl_162_4">4</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000716085/" class="def">Level of evidence: 3iiD</a> or <a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000593395/" class="def">3iiiD</a>] </p><p id="CDR0000062794__229">Adjuvant therapy has no proven benefit and is, therefore, investigational. There have been no well-controlled trials of adjuvant therapy after complete tumor resection.[<a class="bk_pop" href="#CDR0000062794_rl_162_5">5</a>]</p></div><div id="CDR0000062794__230"><h3>Surgical Cytoreduction for Metastases</h3><p id="CDR0000062794__231">Surgery plays a role even in the setting of metastatic disease. The symptoms of metastatic functional pancreatic neuroendocrine tumors (NETs) may be ameliorated by the reduction of overall tumor burden through surgical debulking.</p><p id="CDR0000062794__257">The liver is a common site of metastasis from pancreatic NETs. Because of the slow growth rate of many NETs, liver metastases are often resected when technically feasible. Resection of all grossly visible liver metastases can be associated with long-term survival and, in the case of symptomatic hormonally functional tumors, symptom relief.[<a class="bk_pop" href="#CDR0000062794_rl_162_6">6</a>] Most symptoms from functional tumors respond to this form of surgical debulking. How much of the favorable survival rates is attributable to patient selection factors is not known (e.g., underlying patient condition, extent of metastases, slow doubling time, and so forth). </p><p id="CDR0000062794__260">A variety of alternative approaches to the management of liver metastases have been reported, including gel-foam embolization or transarterial chemoembolization,[<a class="bk_pop" href="#CDR0000062794_rl_162_7">7</a>] radioembolization with radioactive microspheres,[<a class="bk_pop" href="#CDR0000062794_rl_162_8">8</a>-<a class="bk_pop" href="#CDR0000062794_rl_162_10">10</a>] radiofrequency ablation, cryoablation, and percutaneous alcohol ablation. These alternative approaches have been reviewed.[<a class="bk_pop" href="#CDR0000062794_rl_162_11">11</a>]</p><p id="CDR0000062794__232"> Results from surgical resection series appear to be more favorable than with these techniques, and surgery is considered to be the standard approach to resectable liver metastases. However, there are no high-quality studies comparing the various approaches. A systematic review of evidence comparing liver resection versus other treatments for patients with resectable liver neuroendocrine metastases found no randomized trials, or even quasi-experimental, cohort, or case-control studies in which the patient population given the alternative therapies was similar enough to the surgery group to draw reliable conclusions.[<a class="bk_pop" href="#CDR0000062794_rl_162_12">12</a>] The evidence for resection of all grossly visible liver metastases derives solely from case series.[<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000716085/" class="def">Level of evidence: 3iiD</a> or <a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000593395/" class="def">3iiiD</a>]</p><p id="CDR0000062794__234">In most cases, liver metastases are not completely resectable. Cytoreductive surgery, with or without radiofrequency ablation or cryoablation, has been used to palliate symptoms. A systematic review found no randomized or quasi-randomized trials comparing cytoreductive surgery to other palliative approaches such as chemotherapy or tumor product inhibitors.[<a class="bk_pop" href="#CDR0000062794_rl_162_13">13</a>] The evidence for surgical cytoreduction of unresectable liver metastases is restricted to case series [<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000716085/" class="def">Level of evidence: 3iiD</a> or <a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000593395/" class="def">3iiiD</a>], and interpretation of outcomes may be strongly affected by patient selection factors.</p></div><div id="CDR0000062794__235"><h3>Systemic Therapy for Advanced and Metastatic Disease</h3><p id="CDR0000062794__173">Somatostatin analogs may be effective in reducing the symptoms of functional tumors.[<a class="bk_pop" href="#CDR0000062794_rl_162_14">14</a>]</p><p id="CDR0000062794__174">Chemotherapy using drugs such as the following, either alone or in combination, has been shown to have antitumor effects, but evidence is weak or conflicting regarding the impact of chemotherapy on overall survival:[<a class="bk_pop" href="#CDR0000062794_rl_162_15">15</a>-<a class="bk_pop" href="#CDR0000062794_rl_162_17">17</a>]</p><ul id="CDR0000062794__236"><li class="half_rhythm"><div>Streptozocin.</div></li><li class="half_rhythm"><div>Doxorubicin.</div></li><li class="half_rhythm"><div>Fluorouracil.</div></li><li class="half_rhythm"><div>Chlorozotocin.</div></li><li class="half_rhythm"><div>Dacarbazine.</div></li><li class="half_rhythm"><div>Temozolomide.</div></li></ul><p id="CDR0000062794__237"> More recently, a variety of systemic agents have shown biologic or palliative activity, including:[<a class="bk_pop" href="#CDR0000062794_rl_162_5">5</a>,<a class="bk_pop" href="#CDR0000062794_rl_162_18">18</a>]</p><ul id="CDR0000062794__238"><li class="half_rhythm"><div>Tyrosine kinase inhibitors (e.g., sunitinib).</div></li><li class="half_rhythm"><div>Temozolomide.</div></li><li class="half_rhythm"><div>Vascular endothelial growth factor pathway inhibitors.</div></li><li class="half_rhythm"><div>Mammalian target of rapamycin inhibitors (e.g., everolimus).</div></li></ul><p id="CDR0000062794__239">Nearly all of the evidence of activity derives from case series.[<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000587991/" class="def">Level of evidence 3iiiDiv</a>] However, there are ongoing placebo-controlled randomized trials of everolimus [<a class="bk_pop" href="#CDR0000062794_rl_162_19">19</a>] and sunitinib [<a class="bk_pop" href="#CDR0000062794_rl_162_20">20</a>] that have been reported in abstract form showing an increase in progression-free survival in each case.[<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335124/" class="def">Level of evidence 1iDiii</a>]</p><p id="CDR0000062794__240">Favorable responses have been reported in patients with advanced progressive pancreatic NETs after treatment with several radiolabeled somatostatin analogs in which the analogs octreotide, octreotate, lanreotide, or edotreotide are stably attached to the radionuclides indium In 111, yttrium Y 90, or lutetium Lu 177.[<a class="bk_pop" href="#CDR0000062794_rl_162_21">21</a>-
|
|
<a class="bk_pop" href="#CDR0000062794_rl_162_23">23</a>] The relative efficacy of these various compounds is unknown. Study designs have been limited to case series with tumor response, biochemical response, or symptom control as the measure of efficacy.[<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000587991/" class="def">Level of evidence 3iiiDiv</a>]</p><p id="CDR0000062794__241">As noted in each of the clinical situations, there is a paucity or absence of high-level evidence, and a need for randomized controlled trials.[<a class="bk_pop" href="#CDR0000062794_rl_162_5">5</a>]</p></div><div id="CDR0000062794_rl_162"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062794_rl_162_1">Davies K, Conlon KC: Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep 11 (2): 119-27, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19281699" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19281699</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_2">Phan GQ, Yeo CJ, Hruban RH, et al.: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 2 (5): 473-82, 1998 Sep-Oct. [<a href="https://pubmed.ncbi.nlm.nih.gov/18335273" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18335273</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_3">Kazanjian KK, Reber HA, Hines OJ: Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 141 (8): 765-9; discussion 769-70, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16924083" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16924083</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_4">Hochwald SN, Zee S, Conlon KC, et al.: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20 (11): 2633-42, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12039924" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12039924</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_5">Kulke MH, Siu LL, Tepper JE, et al.: Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29 (7): 934-43, 2011. [<a href="/pmc/articles/PMC3068065/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3068065</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21263089" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21263089</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_6">Sarmiento JM, Que FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 12 (1): 231-42, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12735141" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12735141</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_7">Gupta S, Johnson MM, Murthy R, et al.: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (8): 1590-602, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16134179" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16134179</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_8">Nguyen C, Faraggi M, Giraudet AL, et al.: Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 45 (10): 1660-8, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15471830" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15471830</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_9">Kennedy AS, Dezarn WA, McNeillie P, et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31 (3): 271-9, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18525307" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18525307</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_10">King J, Quinn R, Glenn DM, et al.: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 (5): 921-9, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18618495" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18618495</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_11">Siperstein AE, Berber E: Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 25 (6): 693-6, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11376399" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11376399</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_12">Gurusamy KS, Ramamoorthy R, Sharma D, et al.: Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev (2): CD007060, 2009. [<a href="/pmc/articles/PMC7197052/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7197052</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19370671" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19370671</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_13">Gurusamy KS, Pamecha V, Sharma D, et al.: Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev (1): CD007118, 2009. [<a href="/pmc/articles/PMC7388064/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7388064</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19160322" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19160322</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_14">di Bartolomeo M, Bajetta E, Buzzoni R, et al.: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77 (2): 402-8, 1996. [<a href="https://pubmed.ncbi.nlm.nih.gov/8625251" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8625251</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_15">Moertel CG, Lefkopoulo M, Lipsitz S, et al.: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (8): 519-23, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1310159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1310159</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_16">Kouvaraki MA, Ajani JA, Hoff P, et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (23): 4762-71, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15570077" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15570077</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_17">Kulke MH, Hornick JL, Frauenhoffer C, et al.: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15 (1): 338-45, 2009. [<a href="/pmc/articles/PMC3100724/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3100724</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19118063" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19118063</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_18">Yao JC, Lombard-Bohas C, Baudin E, et al.: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28 (1): 69-76, 2010. [<a href="/pmc/articles/PMC4295034/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4295034</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19933912" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19933912</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_19">Yao JC, Shah MH, Ito T, et al.: A randomized, double-blind, placebo-controlled multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). [Abstract] Ann Oncol 21 (Suppl 8): A-LBA9, viii4-5, 2010.</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_20">Raymond E, Niccoli-Sire P, Bang Y: Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). [Abstract] American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium, 22–24 January 2010, Orlando, Florida. A-127, 2010.</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_21">Teunissen JJ, Kwekkeboom DJ, de Jong M, et al.: Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19 (4): 595-616, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16183530" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16183530</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_22">Kwekkeboom DJ, de Herder WW, Kam BL, et al.: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (13): 2124-30, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18445841" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18445841</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_162_23">Bushnell DL, O'Dorisio TM, O'Dorisio MS, et al.: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28 (10): 1652-9, 2010. [<a href="/pmc/articles/PMC4872330/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4872330</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20194865" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20194865</span></a>]</div></li></ol></div></div><div id="CDR0000062794__29"><h2 id="_CDR0000062794__29_">Gastrinoma</h2><p id="CDR0000062794__30">The approach to treatment often depends on the results of preoperative
|
|
localization studies and findings at exploratory laparotomy. At exploration,
|
|
85% of these tumors are found in the gastrinoma triangle with 40% on the
|
|
surface of the pancreas and 40% outside of the pancreas. Only 15% are found
|
|
within the substance of the pancreas. Percutaneous transhepatic venous
|
|
sampling may occasionally provide accurate localization of single sporadic
|
|
gastrinomas. Resection (enucleation of individual tumors, if technically feasible), and even excision of liver metastases, is associated with long-term cure or disease control.[<a class="bk_pop" href="#CDR0000062794_rl_29_1">1</a>]
|
|
</p><p id="CDR0000062794__31"><b>Standard treatment options:
|
|
</b></p><ol id="CDR0000062794__82"><li class="half_rhythm"><div> Single lesion in the head of the pancreas:[<a class="bk_pop" href="#CDR0000062794_rl_29_2">2</a>-<a class="bk_pop" href="#CDR0000062794_rl_29_5">5</a>]<ul id="CDR0000062794__33"><li class="half_rhythm"><div>Enucleation.
|
|
</div></li><li class="half_rhythm"><div>Parietal cell vagotomy and cimetidine.
|
|
</div></li><li class="half_rhythm"><div>Total gastrectomy (rarely used with the advent of current therapies).
|
|
</div></li></ul>
|
|
</div></li><li class="half_rhythm"><div>Single or multiple lesions in the duodenum:[<a class="bk_pop" href="#CDR0000062794_rl_29_2">2</a>-<a class="bk_pop" href="#CDR0000062794_rl_29_5">5</a>]
|
|
<ul id="CDR0000062794__35"><li class="half_rhythm"><div>Pancreatoduodenectomy.
|
|
</div></li></ul></div></li><li class="half_rhythm"><div>Single lesion in the body/tail of the pancreas:[<a class="bk_pop" href="#CDR0000062794_rl_29_2">2</a>-<a class="bk_pop" href="#CDR0000062794_rl_29_5">5</a>]
|
|
<ul id="CDR0000062794__37"><li class="half_rhythm"><div>Resection of body/tail.
|
|
</div></li></ul></div></li><li class="half_rhythm"><div>Multiple lesions in the pancreas:[<a class="bk_pop" href="#CDR0000062794_rl_29_2">2</a>-<a class="bk_pop" href="#CDR0000062794_rl_29_5">5</a>]
|
|
<ul id="CDR0000062794__39"><li class="half_rhythm"><div>Resection of body/tail and, if residual disease is present,
|
|
</div></li><li class="half_rhythm"><div>Parietal cell vagotomy and cimetidine, or
|
|
</div></li><li class="half_rhythm"><div>Total gastrectomy (rarely used with the advent of current therapies).
|
|
</div></li></ul></div></li><li class="half_rhythm"><div> No tumor found:
|
|
<ul id="CDR0000062794__41"><li class="half_rhythm"><div>Parietal cell vagotomy and cimetidine.
|
|
</div></li><li class="half_rhythm"><div>Total gastrectomy (rarely used with the advent of current therapies).
|
|
</div></li></ul></div></li><li class="half_rhythm"><div>Liver metastases:[<a class="bk_pop" href="#CDR0000062794_rl_29_6">6</a>-<a class="bk_pop" href="#CDR0000062794_rl_29_13">13</a>]<ul id="CDR0000062794__43"><li class="half_rhythm"><div>Liver resection where possible.</div></li><li class="half_rhythm"><div>Radiofrequency ablation or cryosurgical ablation.</div></li><li class="half_rhythm"><div>Chemoembolization of liver.
|
|
</div></li></ul></div></li><li class="half_rhythm"><div>Metastatic disease or disease refractory to surgery and cimetidine:[<a class="bk_pop" href="#CDR0000062794_rl_29_14">14</a>-
|
|
<a class="bk_pop" href="#CDR0000062794_rl_29_23">23</a>]<ul id="CDR0000062794__45"><li class="half_rhythm"><div>Chemotherapy
|
|
</div></li><li class="half_rhythm"><div>Somatostatin analog therapy.
|
|
</div></li></ul></div></li></ol><p id="CDR0000062794__47">Patients with hepatic-dominant disease and substantial symptoms caused by tumor
|
|
bulk or hormone-release syndromes may benefit from procedures that reduce
|
|
hepatic arterial blood flow to metastases (hepatic arterial occlusion with
|
|
embolization or with chemoembolization). Such treatment may also be combined
|
|
with systemic chemotherapy in selected patients. Treatment with proton pump inhibitors or H2 blocking agents may aid in control of peptic symptoms.
|
|
</p><p id="CDR0000062794__181">In the era of proton pump inhibitors and H2 blocking agents, the potentially lethal hyperacidity and hypersecretory states induced by excessive gastrin production can usually be controlled. In a series of 212 patients with Zollinger-Ellison syndrome (ZES), no patients died of causes related to acid hypersecretion. Of those patients, only 2.3% had been subjected to total gastrectomy, and the cohort upon which the report was based had a long median follow-up period of 13.8 years. Although 32% of the patients died during the course of the study, only 50% of the 67 deaths were attributable to ZES-related causes. Those causes were mainly liver metastases with progressive anorexia and cachexia (67%) or secondary endocrine tumors consequent to multiple endocrine neoplasia type 1 syndrome. The development of bone or liver metastases (especially diffuse liver disease) or of ectopic Cushing syndrome during the study period predicted for decreased survival times.[<a class="bk_pop" href="#CDR0000062794_rl_29_24">24</a>]</p><div id="CDR0000062794__TrialSearch_29_sid_5"><h3>Current Clinical Trials</h3><p id="CDR0000062794__TrialSearch_29_22">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062794_rl_29"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062794_rl_29_1">Norton JA, Fraker DL, Alexander HR, et al.: Surgery increases survival in patients with gastrinoma. Ann Surg 244 (3): 410-9, 2006. [<a href="/pmc/articles/PMC1856542/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1856542</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16926567" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16926567</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_2">Davies K, Conlon KC: Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep 11 (2): 119-27, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19281699" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19281699</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_3">Phan GQ, Yeo CJ, Hruban RH, et al.: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 2 (5): 473-82, 1998 Sep-Oct. [<a href="https://pubmed.ncbi.nlm.nih.gov/18335273" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18335273</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_4">Kazanjian KK, Reber HA, Hines OJ: Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 141 (8): 765-9; discussion 769-70, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16924083" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16924083</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_5">Hochwald SN, Zee S, Conlon KC, et al.: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20 (11): 2633-42, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12039924" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12039924</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_6">Sarmiento JM, Que FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 12 (1): 231-42, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12735141" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12735141</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_7">Gupta S, Johnson MM, Murthy R, et al.: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (8): 1590-602, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16134179" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16134179</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_8">Nguyen C, Faraggi M, Giraudet AL, et al.: Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 45 (10): 1660-8, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15471830" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15471830</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_9">Kennedy AS, Dezarn WA, McNeillie P, et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31 (3): 271-9, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18525307" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18525307</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_10">King J, Quinn R, Glenn DM, et al.: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 (5): 921-9, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18618495" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18618495</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_11">Siperstein AE, Berber E: Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 25 (6): 693-6, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11376399" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11376399</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_12">Gurusamy KS, Ramamoorthy R, Sharma D, et al.: Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev (2): CD007060, 2009. [<a href="/pmc/articles/PMC7197052/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7197052</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19370671" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19370671</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_13">Gurusamy KS, Pamecha V, Sharma D, et al.: Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev (1): CD007118, 2009. [<a href="/pmc/articles/PMC7388064/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7388064</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19160322" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19160322</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_14">di Bartolomeo M, Bajetta E, Buzzoni R, et al.: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77 (2): 402-8, 1996. [<a href="https://pubmed.ncbi.nlm.nih.gov/8625251" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8625251</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_15">Moertel CG, Lefkopoulo M, Lipsitz S, et al.: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (8): 519-23, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1310159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1310159</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_16">Kouvaraki MA, Ajani JA, Hoff P, et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (23): 4762-71, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15570077" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15570077</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_17">Kulke MH, Hornick JL, Frauenhoffer C, et al.: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15 (1): 338-45, 2009. [<a href="/pmc/articles/PMC3100724/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3100724</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19118063" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19118063</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_18">Yao JC, Lombard-Bohas C, Baudin E, et al.: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28 (1): 69-76, 2010. [<a href="/pmc/articles/PMC4295034/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4295034</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19933912" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19933912</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_19">Yao JC, Shah MH, Ito T, et al.: A randomized, double-blind, placebo-controlled multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). [Abstract] Ann Oncol 21 (Suppl 8): A-LBA9, viii4-5, 2010.</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_20">Raymond E, Niccoli-Sire P, Bang Y: Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). [Abstract] American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium, 22–24 January 2010, Orlando, Florida. A-127, 2010.</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_21">Teunissen JJ, Kwekkeboom DJ, de Jong M, et al.: Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19 (4): 595-616, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16183530" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16183530</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_22">Kwekkeboom DJ, de Herder WW, Kam BL, et al.: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (13): 2124-30, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18445841" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18445841</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_23">Bushnell DL, O'Dorisio TM, O'Dorisio MS, et al.: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28 (10): 1652-9, 2010. [<a href="/pmc/articles/PMC4872330/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4872330</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20194865" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20194865</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_29_24">Kvols LK, Buck M, Moertel CG, et al.: Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 107 (2): 162-8, 1987. [<a href="https://pubmed.ncbi.nlm.nih.gov/2886085" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2886085</span></a>]</div></li></ol></div></div><div id="CDR0000062794__48"><h2 id="_CDR0000062794__48_">Insulinoma</h2><p id="CDR0000062794__182">Curative surgical excision, by open laparotomy or laparoscopy, is the treatment of choice when possible. The open surgical approach is used if the tumor is suspected to be malignant because en bloc lymphadenectomy is performed for malignant tumors without distant metastases. Intraoperative ultrasound aids the localization of tumor extent and the relationship to other anatomic structures.[<a class="bk_pop" href="#CDR0000062794_rl_48_1">1</a>] </p><p id="CDR0000062794__49"><b>Standard treatment options:</b>
|
|
</p><ol id="CDR0000062794__83"><li class="half_rhythm"><div>Single, small lesion in the head or tail of the pancreas:[<a class="bk_pop" href="#CDR0000062794_rl_48_1">1</a>-<a class="bk_pop" href="#CDR0000062794_rl_48_4">4</a>]
|
|
<ul id="CDR0000062794__51"><li class="half_rhythm"><div>Enucleation, if feasible.
|
|
</div></li></ul></div></li><li class="half_rhythm"><div> Large lesion in the head of the pancreas that is not amenable to enucleation:[<a class="bk_pop" href="#CDR0000062794_rl_48_1">1</a>-<a class="bk_pop" href="#CDR0000062794_rl_48_4">4</a>]<ul id="CDR0000062794__183"><li class="half_rhythm"><div>Pancreaticoduodenectomy. </div></li></ul></div></li><li class="half_rhythm"><div>Single, large lesion in the body/tail:[<a class="bk_pop" href="#CDR0000062794_rl_48_1">1</a>-<a class="bk_pop" href="#CDR0000062794_rl_48_4">4</a>]<ul id="CDR0000062794__242"><li class="half_rhythm"><div>Distal pancreatectomy.</div></li></ul>
|
|
</div></li><li class="half_rhythm"><div>Multiple lesions: occur in 10%, often in association with multiple endocrine neoplasia syndrome type 1:[<a class="bk_pop" href="#CDR0000062794_rl_48_1">1</a>-<a class="bk_pop" href="#CDR0000062794_rl_48_4">4</a>]<ul id="CDR0000062794__184"><li class="half_rhythm"><div>Distal pancreatectomy with enucleation of tumors in the head of the pancreas.</div></li></ul></div></li><li class="half_rhythm"><div>Metastatic lesions: lymph nodes or distant sites:[<a class="bk_pop" href="#CDR0000062794_rl_48_5">5</a>-<a class="bk_pop" href="#CDR0000062794_rl_48_12">12</a>]
|
|
<ul id="CDR0000062794__57"><li class="half_rhythm"><div>Resect when possible.</div></li><li class="half_rhythm"><div>Consider radiofrequency or cryosurgical ablation, if not resectable.</div></li></ul></div></li><li class="half_rhythm"><div>Unresectable:[<a class="bk_pop" href="#CDR0000062794_rl_48_13">13</a>-
|
|
<a class="bk_pop" href="#CDR0000062794_rl_48_22">22</a>]<ul id="CDR0000062794__59"><li class="half_rhythm"><div>Combination chemotherapy.
|
|
</div></li><li class="half_rhythm"><div>Pharmacologic palliation: diazoxide 300 to 500 mg/day.
|
|
</div></li><li class="half_rhythm"><div>Somatostatin analogue therapy.
|
|
</div></li></ul></div></li></ol><p id="CDR0000062794__61">Patients with hepatic-dominant disease and substantial symptoms caused by tumor
|
|
bulk or hormone-release syndromes may benefit from procedures that reduce
|
|
hepatic arterial blood flow to metastases (hepatic arterial occlusion with
|
|
embolization or with chemoembolization).[<a class="bk_pop" href="#CDR0000062794_rl_48_6">6</a>,<a class="bk_pop" href="#CDR0000062794_rl_48_8">8</a>-<a class="bk_pop" href="#CDR0000062794_rl_48_12">12</a>] Such treatment may also be combined
|
|
with systemic chemotherapy in selected patients.
|
|
</p><div id="CDR0000062794__TrialSearch_48_sid_6"><h3>Current Clinical Trials</h3><p id="CDR0000062794__TrialSearch_48_22">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062794_rl_48"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062794_rl_48_1">Davies K, Conlon KC: Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep 11 (2): 119-27, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19281699" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19281699</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_2">Phan GQ, Yeo CJ, Hruban RH, et al.: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 2 (5): 473-82, 1998 Sep-Oct. [<a href="https://pubmed.ncbi.nlm.nih.gov/18335273" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18335273</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_3">Kazanjian KK, Reber HA, Hines OJ: Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 141 (8): 765-9; discussion 769-70, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16924083" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16924083</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_4">Hochwald SN, Zee S, Conlon KC, et al.: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20 (11): 2633-42, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12039924" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12039924</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_5">Sarmiento JM, Que FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 12 (1): 231-42, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12735141" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12735141</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_6">Gupta S, Johnson MM, Murthy R, et al.: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (8): 1590-602, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16134179" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16134179</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_7">Nguyen C, Faraggi M, Giraudet AL, et al.: Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 45 (10): 1660-8, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15471830" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15471830</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_8">Kennedy AS, Dezarn WA, McNeillie P, et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31 (3): 271-9, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18525307" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18525307</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_9">King J, Quinn R, Glenn DM, et al.: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 (5): 921-9, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18618495" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18618495</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_10">Siperstein AE, Berber E: Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 25 (6): 693-6, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11376399" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11376399</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_11">Gurusamy KS, Ramamoorthy R, Sharma D, et al.: Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev (2): CD007060, 2009. [<a href="/pmc/articles/PMC7197052/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7197052</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19370671" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19370671</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_12">Gurusamy KS, Pamecha V, Sharma D, et al.: Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev (1): CD007118, 2009. [<a href="/pmc/articles/PMC7388064/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7388064</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19160322" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19160322</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_13">di Bartolomeo M, Bajetta E, Buzzoni R, et al.: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77 (2): 402-8, 1996. [<a href="https://pubmed.ncbi.nlm.nih.gov/8625251" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8625251</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_14">Moertel CG, Lefkopoulo M, Lipsitz S, et al.: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (8): 519-23, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1310159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1310159</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_15">Kouvaraki MA, Ajani JA, Hoff P, et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (23): 4762-71, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15570077" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15570077</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_16">Kulke MH, Hornick JL, Frauenhoffer C, et al.: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15 (1): 338-45, 2009. [<a href="/pmc/articles/PMC3100724/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3100724</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19118063" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19118063</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_17">Yao JC, Lombard-Bohas C, Baudin E, et al.: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28 (1): 69-76, 2010. [<a href="/pmc/articles/PMC4295034/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4295034</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19933912" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19933912</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_18">Yao JC, Shah MH, Ito T, et al.: A randomized, double-blind, placebo-controlled multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). [Abstract] Ann Oncol 21 (Suppl 8): A-LBA9, viii4-5, 2010.</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_19">Raymond E, Niccoli-Sire P, Bang Y: Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). [Abstract] American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium, 22–24 January 2010, Orlando, Florida. A-127, 2010.</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_20">Teunissen JJ, Kwekkeboom DJ, de Jong M, et al.: Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19 (4): 595-616, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16183530" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16183530</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_21">Kwekkeboom DJ, de Herder WW, Kam BL, et al.: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (13): 2124-30, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18445841" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18445841</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_48_22">Bushnell DL, O'Dorisio TM, O'Dorisio MS, et al.: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28 (10): 1652-9, 2010. [<a href="/pmc/articles/PMC4872330/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4872330</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20194865" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20194865</span></a>]</div></li></ol></div></div><div id="CDR0000062794__88"><h2 id="_CDR0000062794__88_">Glucagonoma</h2><p id="CDR0000062794__185">As with the other pancreatic neuroendocrine tumors, the mainstay of therapy is surgical resection, and extended survival is possible even when the disease is metastatic. Resection of metastases is also a consideration when feasible.[<a class="bk_pop" href="#CDR0000062794_rl_88_1">1</a>]</p><p id="CDR0000062794__89"><b>Standard treatment options:</b></p><ol id="CDR0000062794__84"><li class="half_rhythm"><div>Single, small lesion in the head or tail of the pancreas:[<a class="bk_pop" href="#CDR0000062794_rl_88_1">1</a>-<a class="bk_pop" href="#CDR0000062794_rl_88_4">4</a>]<ul id="CDR0000062794__66"><li class="half_rhythm"><div>Enucleation, if feasible.
|
|
</div></li></ul></div></li><li class="half_rhythm"><div>Large lesion in the head of the pancreas that is not amenable to enucleation:[<a class="bk_pop" href="#CDR0000062794_rl_88_1">1</a>-<a class="bk_pop" href="#CDR0000062794_rl_88_4">4</a>]<ul id="CDR0000062794__186"><li class="half_rhythm"><div>Pancreaticoduodenectomy.</div></li></ul></div></li><li class="half_rhythm"><div>Single, large lesion in the body/tail:[<a class="bk_pop" href="#CDR0000062794_rl_88_1">1</a>-<a class="bk_pop" href="#CDR0000062794_rl_88_4">4</a>]<ul id="CDR0000062794__68"><li class="half_rhythm"><div>Distal pancreatectomy.
|
|
</div></li></ul></div></li><li class="half_rhythm"><div>Multiple lesions:[<a class="bk_pop" href="#CDR0000062794_rl_88_1">1</a>-<a class="bk_pop" href="#CDR0000062794_rl_88_4">4</a>]
|
|
<ul id="CDR0000062794__70"><li class="half_rhythm"><div>Enucleation, if feasible. </div></li><li class="half_rhythm"><div>Resect body and tail otherwise.
|
|
</div></li></ul></div></li><li class="half_rhythm"><div>Metastatic disease: lymph nodes or distant sites:[<a class="bk_pop" href="#CDR0000062794_rl_88_5">5</a>-<a class="bk_pop" href="#CDR0000062794_rl_88_12">12</a>]
|
|
<ul id="CDR0000062794__72"><li class="half_rhythm"><div>Resect when possible.</div></li><li class="half_rhythm"><div> Consider radiofrequency or cryosurgical ablation, if not resectable.
|
|
</div></li></ul></div></li><li class="half_rhythm"><div> Unresectable disease:[<a class="bk_pop" href="#CDR0000062794_rl_88_13">13</a>-
|
|
<a class="bk_pop" href="#CDR0000062794_rl_88_22">22</a>]
|
|
<ul id="CDR0000062794__74"><li class="half_rhythm"><div>Combination chemotherapy.
|
|
</div></li><li class="half_rhythm"><div>Somatostatin analog therapy.
|
|
Necrotizing erythema of glucagonoma may be relieved in 24 hours with somatostatin analog, with nearly complete disappearance within 1 week.</div></li></ul></div></li></ol><p id="CDR0000062794__90">Patients with hepatic-dominant disease and substantial symptoms caused by tumor
|
|
bulk or hormone-release syndromes may benefit from procedures that reduce
|
|
hepatic arterial blood flow to metastases (hepatic arterial occlusion with
|
|
embolization or with chemoembolization).[<a class="bk_pop" href="#CDR0000062794_rl_88_6">6</a>,<a class="bk_pop" href="#CDR0000062794_rl_88_8">8</a>-<a class="bk_pop" href="#CDR0000062794_rl_88_12">12</a>] Such treatment may also be combined
|
|
with systemic chemotherapy in selected patients.</p><div id="CDR0000062794__TrialSearch_88_sid_7"><h3>Current Clinical Trials</h3><p id="CDR0000062794__TrialSearch_88_22">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062794_rl_88"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062794_rl_88_1">Davies K, Conlon KC: Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep 11 (2): 119-27, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19281699" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19281699</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_2">Phan GQ, Yeo CJ, Hruban RH, et al.: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 2 (5): 473-82, 1998 Sep-Oct. [<a href="https://pubmed.ncbi.nlm.nih.gov/18335273" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18335273</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_3">Kazanjian KK, Reber HA, Hines OJ: Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 141 (8): 765-9; discussion 769-70, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16924083" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16924083</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_4">Hochwald SN, Zee S, Conlon KC, et al.: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20 (11): 2633-42, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12039924" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12039924</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_5">Sarmiento JM, Que FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 12 (1): 231-42, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12735141" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12735141</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_6">Gupta S, Johnson MM, Murthy R, et al.: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (8): 1590-602, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16134179" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16134179</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_7">Nguyen C, Faraggi M, Giraudet AL, et al.: Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 45 (10): 1660-8, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15471830" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15471830</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_8">Kennedy AS, Dezarn WA, McNeillie P, et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31 (3): 271-9, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18525307" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18525307</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_9">King J, Quinn R, Glenn DM, et al.: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 (5): 921-9, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18618495" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18618495</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_10">Siperstein AE, Berber E: Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 25 (6): 693-6, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11376399" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11376399</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_11">Gurusamy KS, Ramamoorthy R, Sharma D, et al.: Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev (2): CD007060, 2009. [<a href="/pmc/articles/PMC7197052/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7197052</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19370671" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19370671</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_12">Gurusamy KS, Pamecha V, Sharma D, et al.: Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev (1): CD007118, 2009. [<a href="/pmc/articles/PMC7388064/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7388064</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19160322" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19160322</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_13">di Bartolomeo M, Bajetta E, Buzzoni R, et al.: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77 (2): 402-8, 1996. [<a href="https://pubmed.ncbi.nlm.nih.gov/8625251" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8625251</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_14">Moertel CG, Lefkopoulo M, Lipsitz S, et al.: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (8): 519-23, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1310159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1310159</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_15">Kouvaraki MA, Ajani JA, Hoff P, et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (23): 4762-71, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15570077" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15570077</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_16">Kulke MH, Hornick JL, Frauenhoffer C, et al.: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15 (1): 338-45, 2009. [<a href="/pmc/articles/PMC3100724/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3100724</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19118063" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19118063</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_17">Yao JC, Lombard-Bohas C, Baudin E, et al.: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28 (1): 69-76, 2010. [<a href="/pmc/articles/PMC4295034/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4295034</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19933912" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19933912</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_18">Yao JC, Shah MH, Ito T, et al.: A randomized, double-blind, placebo-controlled multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). [Abstract] Ann Oncol 21 (Suppl 8): A-LBA9, viii4-5, 2010.</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_19">Raymond E, Niccoli-Sire P, Bang Y: Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). [Abstract] American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium, 22–24 January 2010, Orlando, Florida. A-127, 2010.</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_20">Teunissen JJ, Kwekkeboom DJ, de Jong M, et al.: Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19 (4): 595-616, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16183530" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16183530</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_21">Kwekkeboom DJ, de Herder WW, Kam BL, et al.: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (13): 2124-30, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18445841" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18445841</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_88_22">Bushnell DL, O'Dorisio TM, O'Dorisio MS, et al.: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28 (10): 1652-9, 2010. [<a href="/pmc/articles/PMC4872330/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4872330</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20194865" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20194865</span></a>]</div></li></ol></div></div><div id="CDR0000062794__62"><h2 id="_CDR0000062794__62_">Miscellaneous Islet Cell Tumors</h2><div id="CDR0000062794__187"><h3>VIPoma</h3><p id="CDR0000062794__188">Immediate fluid resuscitation is often necessary to correct the electrolyte and fluid problems that occur as a result of the watery diarrhea, hypokalemia, and achlorhydria that patients experience. Somatostatin analogs are also used to ameliorate the large fluid and electrolyte losses. Once patients are stabilized, excision of the primary tumor and regional nodes is the first line of therapy for clinically localized disease. In the case of locally advanced or metastatic disease, where curative resection is not possible, debulking and removal of gross disease, including metastases, should be considered to alleviate the characteristic manifestations of vasoactive intestinal peptide overproduction.[<a class="bk_pop" href="#CDR0000062794_rl_62_1">1</a>] (Refer to the <a href="#CDR0000062794__162">Treatment Option Overview</a> section of this summary for information about the remaining principles of therapy.)</p></div><div id="CDR0000062794__189"><h3>Somatostatinoma</h3><p id="CDR0000062794__190">Complete excision is the therapy of choice, if technically possible. However, metastases often preclude curative resection, and palliative debulking can be considered to relieve symptoms.[<a class="bk_pop" href="#CDR0000062794_rl_62_1">1</a>] (Refer to the <a href="#CDR0000062794__162">Treatment Option Overview</a> section of this summary for information about the remaining principles of therapy.)</p></div><div id="CDR0000062794__191"><h3>Other Pancreatic Neuroendocrine Tumors </h3><p id="CDR0000062794__192">For these very rare tumors, complete surgical excision is the only curative option when technically possible, and debulking or somatostatin analogs are used for palliation of symptoms if the tumor is functional. (Refer to the <a href="#CDR0000062794__162">Treatment Option Overview</a> section of this summary for information about the remaining principles of therapy.) </p></div><div id="CDR0000062794__TrialSearch_62_sid_8"><h3>Current Clinical Trials</h3><p id="CDR0000062794__TrialSearch_62_22">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062794_rl_62"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062794_rl_62_1">Davies K, Conlon KC: Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep 11 (2): 119-27, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19281699" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19281699</span></a>]</div></li></ol></div></div><div id="CDR0000062794__78"><h2 id="_CDR0000062794__78_">Recurrent and Progressive Pancreatic Neuroendocrine Tumors</h2><p id="CDR0000062794__193">There is no established therapy for pancreatic neuroendocrine tumors that recur or progress after previous therapy.[<a class="bk_pop" href="#CDR0000062794_rl_78_1">1</a>] Deciding on further treatment depends on many factors, including:</p><ul id="CDR0000062794__194"><li class="half_rhythm"><div>The specific
|
|
cancer.</div></li><li class="half_rhythm"><div> Previous treatment.</div></li><li class="half_rhythm"><div>Site of recurrence.</div></li><li class="half_rhythm"><div>Individual patient
|
|
considerations.</div></li></ul><p id="CDR0000062794__195">Attempts at
|
|
re-resection of local tumors that have recurred or re-resection of metastatic lesions may offer palliation, when technically feasible. Intra-arterial chemotherapy
|
|
is a consideration for patients with liver metastases. Patients with hepatic-dominant disease and
|
|
substantial symptoms caused by tumor bulk or hormone-release syndromes may
|
|
benefit from continuous-infusion intra-arterial chemotherapy or procedures that
|
|
reduce hepatic arterial blood flow to metastases (hepatic arterial occlusion
|
|
with embolization or with chemoembolization).[<a class="bk_pop" href="#CDR0000062794_rl_78_2">2</a>-<a class="bk_pop" href="#CDR0000062794_rl_78_7">7</a>] Such treatment may also be
|
|
combined with systemic chemotherapy. A variety of systemic agents have shown biologic or palliative activity,[<a class="bk_pop" href="#CDR0000062794_rl_78_1">1</a>,<a class="bk_pop" href="#CDR0000062794_rl_78_8">8</a>] including the following:</p><ul id="CDR0000062794__196"><li class="half_rhythm"><div>Somatostatin analogs.</div></li><li class="half_rhythm"><div>Radiolabeled somatostatin analogs.[<a class="bk_pop" href="#CDR0000062794_rl_78_9">9</a>-<a class="bk_pop" href="#CDR0000062794_rl_78_11">11</a>]</div></li><li class="half_rhythm"><div>Tyrosine kinase inhibitors (e.g., sunitinib).</div></li><li class="half_rhythm"><div>Temozolomide.</div></li><li class="half_rhythm"><div>Vascular endothelial growth factor pathway inhibitors.</div></li><li class="half_rhythm"><div>Mammalian target of rapamycin inhibitors (e.g., everolimus).</div></li></ul><div id="CDR0000062794__TrialSearch_78_sid_9"><h3>Current Clinical Trials</h3><p id="CDR0000062794__TrialSearch_78_22">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062794_rl_78"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062794_rl_78_1">Kulke MH, Siu LL, Tepper JE, et al.: Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29 (7): 934-43, 2011. [<a href="/pmc/articles/PMC3068065/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3068065</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21263089" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21263089</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_78_2">Gupta S, Johnson MM, Murthy R, et al.: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (8): 1590-602, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16134179" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16134179</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_78_3">Kennedy AS, Dezarn WA, McNeillie P, et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31 (3): 271-9, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18525307" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18525307</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_78_4">King J, Quinn R, Glenn DM, et al.: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 (5): 921-9, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18618495" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18618495</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_78_5">Siperstein AE, Berber E: Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 25 (6): 693-6, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11376399" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11376399</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_78_6">Gurusamy KS, Ramamoorthy R, Sharma D, et al.: Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev (2): CD007060, 2009. [<a href="/pmc/articles/PMC7197052/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7197052</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19370671" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19370671</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_78_7">Gurusamy KS, Pamecha V, Sharma D, et al.: Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev (1): CD007118, 2009. [<a href="/pmc/articles/PMC7388064/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7388064</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19160322" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19160322</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_78_8">Yao JC, Lombard-Bohas C, Baudin E, et al.: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28 (1): 69-76, 2010. [<a href="/pmc/articles/PMC4295034/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4295034</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19933912" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19933912</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_78_9">Teunissen JJ, Kwekkeboom DJ, de Jong M, et al.: Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19 (4): 595-616, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16183530" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16183530</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_78_10">Kwekkeboom DJ, de Herder WW, Kam BL, et al.: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (13): 2124-30, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18445841" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18445841</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062794_rl_78_11">Bushnell DL, O'Dorisio TM, O'Dorisio MS, et al.: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28 (10): 1652-9, 2010. [<a href="/pmc/articles/PMC4872330/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4872330</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20194865" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20194865</span></a>]</div></li></ol></div></div><div id="CDR0000062794__91"><h2 id="_CDR0000062794__91_">Changes to This Summary (12/13/2019)</h2><p id="CDR0000062794__92">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</p><p id="CDR0000062794__2030"><b><a href="#CDR0000062794__1">General Information About Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)
|
|
</a></b></p><p id="CDR0000062794__2031">Revised <a href="#CDR0000062794__264">text</a> to state that pancreatic neuroendocrine tumors account for less than 2% of pancreatic malignancies and overall have a better prognosis than the more common pancreatic exocrine tumors (cited American Joint Committee on Cancer (AJCC) as reference 2).
|
|
</p><p id="CDR0000062794__273"><b><a href="#CDR0000062794__199">Stage Information for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)</a></b></p><p id="CDR0000062794__2023">Updated <a href="#CDR0000062794__259">staging information</a> for 2017 (cited AJCC as reference 1).</p><p id="CDR0000062794__disclaimerHP_3">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Adult Treatment Editorial Board</a>, which is
|
|
editorially independent of NCI. The summary reflects an independent review of
|
|
the literature and does not represent a policy statement of NCI or NIH. More
|
|
information about summary policies and the role of the PDQ Editorial Boards in
|
|
maintaining the PDQ summaries can be found on the <a href="#CDR0000062794__AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ® - NCI's Comprehensive Cancer Database</a> pages.
|
|
</p></div><div id="CDR0000062794__AboutThis_1"><h2 id="_CDR0000062794__AboutThis_1_">About This PDQ Summary</h2><div id="CDR0000062794__AboutThis_2"><h3>Purpose of This Summary</h3><p id="CDR0000062794__AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of pancreatic neuroendocrine tumors (islet cell tumors). It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.</p></div><div id="CDR0000062794__AboutThis_4"><h3>Reviewers and Updates</h3><p id="CDR0000062794__AboutThis_5">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Adult Treatment Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="CDR0000062794__AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</p><ul id="CDR0000062794__AboutThis_6"><li class="half_rhythm"><div>be discussed at a meeting,</div></li><li class="half_rhythm"><div>be cited with text, or</div></li><li class="half_rhythm"><div>replace or update an existing article that is already cited.</div></li></ul><p id="CDR0000062794__AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.</p><p>The lead reviewers for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment are:</p><ul><li class="half_rhythm"><div>Russell S. Berman, MD (New York University School of Medicine)</div></li><li class="half_rhythm"><div>Ann W. Gramza, MD (Georgetown Lombardi Comprehensive Cancer Center)</div></li><li class="half_rhythm"><div>Franco M. Muggia, MD (New York University Medical Center)</div></li><li class="half_rhythm"><div>Jaydira del Rivero, MD (National Cancer Institute)</div></li></ul><p id="CDR0000062794__AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></div><div id="CDR0000062794__AboutThis_10"><h3>Levels of Evidence</h3><p id="CDR0000062794__AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <a href="/books/n/pdqcis/CDR0000062796/">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></div><div id="CDR0000062794__AboutThis_12"><h3>Permission to Use This Summary</h3><p id="CDR0000062794__AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</p><p id="CDR0000062794__AboutThis_14">The preferred citation for this PDQ summary is:</p><p id="CDR0000062794__AboutThis_15">PDQ® Adult Treatment Editorial Board. PDQ Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: <a href="https://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq</a>. Accessed <MM/DD/YYYY>. [PMID: 26389309]</p><p id="CDR0000062794__AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Visuals Online</a>, a collection of over 2,000 scientific images.
|
|
</p></div><div id="CDR0000062794__AboutThis_17"><h3>Disclaimer</h3><p id="CDR0000062794__AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Managing Cancer Care</a> page.</p></div><div id="CDR0000062794__AboutThis_20"><h3>Contact Us</h3><p id="CDR0000062794__AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website’s <a href="https://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>.</p></div></div></div></div>
|
|
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK65870</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/26389309" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">26389309</a></span></div></div></div>
|
|
|
|
</div>
|
|
|
|
<!-- Custom content below content -->
|
|
<div class="col4">
|
|
|
|
</div>
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<!-- Custom contetnt below bottom nav -->
|
|
<div class="col5">
|
|
|
|
</div>
|
|
</div>
|
|
|
|
<div id="rightcolumn" class="four_col col last">
|
|
<!-- Custom content above discovery portlets -->
|
|
<div class="col6">
|
|
<div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK65870&db=books">Share</a></div>
|
|
|
|
</div>
|
|
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK65870.4/?report=reader">PubReader</a></li><li><a href="/books/NBK65870.4/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK65870" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK65870" style="display:none" title="Cite this Page"><div class="bk_tt">PDQ Adult Treatment Editorial Board. Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®): Health Professional Version. 2019 Dec 13. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. <span class="bk_cite_avail"></span></div></div></li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Version History</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter shutter_closed" title="Show/hide content" remembercollapsed="true" pgsec_name="version_history" id="Shutter"></a></div><div class="portlet_content" style="display: none;"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><span class="bk_col_itm"><a href="/books/NBK65870.7/">NBK65870.7</a></span> August 16, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK65870.6/">NBK65870.6</a></span> August 19, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK65870.5/">NBK65870.5</a></span> January 2, 2020</li><li><span class="bk_col_itm">NBK65870.4</span> December 13, 2019 (Displayed Version)</li><li><span class="bk_col_itm"><a href="/books/NBK65870.3/">NBK65870.3</a></span> April 15, 2019</li><li><span class="bk_col_itm"><a href="/books/NBK65870.2/">NBK65870.2</a></span> February 8, 2018</li><li><span class="bk_col_itm"><a href="/books/NBK65870.1/">NBK65870.1</a></span> April 30, 2015</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this Page</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#CDR0000062794__1" ref="log$=inpage&link_id=inpage">General Information About Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)</a></li><li><a href="#CDR0000062794__4" ref="log$=inpage&link_id=inpage">Cellular Classification of Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)</a></li><li><a href="#CDR0000062794__199" ref="log$=inpage&link_id=inpage">Stage Information for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)</a></li><li><a href="#CDR0000062794__162" ref="log$=inpage&link_id=inpage">Treatment Option Overview</a></li><li><a href="#CDR0000062794__29" ref="log$=inpage&link_id=inpage">Gastrinoma</a></li><li><a href="#CDR0000062794__48" ref="log$=inpage&link_id=inpage">Insulinoma</a></li><li><a href="#CDR0000062794__88" ref="log$=inpage&link_id=inpage">Glucagonoma</a></li><li><a href="#CDR0000062794__62" ref="log$=inpage&link_id=inpage">Miscellaneous Islet Cell Tumors</a></li><li><a href="#CDR0000062794__78" ref="log$=inpage&link_id=inpage">Recurrent and Progressive Pancreatic Neuroendocrine Tumors</a></li><li><a href="#CDR0000062794__91" ref="log$=inpage&link_id=inpage">Changes to This Summary (12/13/2019)</a></li><li><a href="#CDR0000062794__AboutThis_1" ref="log$=inpage&link_id=inpage">About This PDQ Summary</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related publications</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK65902/">Patient Version</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&DbFrom=books&Cmd=Link&LinkName=books_pmc_refs&IdsFromResult=2822048" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&DbFrom=books&Cmd=Link&LinkName=books_pubmed_refs&IdsFromResult=2822048" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389233" ref="ordinalpos=1&linkpos=1&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Adult Treatment Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389449" ref="ordinalpos=1&linkpos=2&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ovarian Germ Cell Tumors Treatment (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ovarian Germ Cell Tumors Treatment (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Adult Treatment Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389287" ref="ordinalpos=1&linkpos=3&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gonzalez Regimen (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gonzalez Regimen (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389193" ref="ordinalpos=1&linkpos=4&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nasopharyngeal Carcinoma Treatment (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nasopharyngeal Carcinoma Treatment (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Adult Treatment Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389476" ref="ordinalpos=1&linkpos=5&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Thymoma and Thymic Carcinoma Treatment (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Thymoma and Thymic Carcinoma Treatment (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Adult Treatment Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed_reviews&uid=26389309" ref="ordinalpos=1&log$=relatedreviews_seeall&logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed&uid=26389309" ref="ordinalpos=1&log$=relatedarticles_seeall&logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=67c95a11ab82281a8065e91b">Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®) - PDQ Canc...</a><div class="ralinkpop offscreen_noflow">Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_qry two_line"><a class="htb" ref="log$=activity&linkpos=2" href="/portal/utils/pageresolver.fcgi?recordid=67c95a01ab82281a80655217">PMC Links for Books (Select 2829626) <span class="number">(17)</span></a><div class="tertiary">PMC</div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=3" href="/portal/utils/pageresolver.fcgi?recordid=67c959ffab82281a80654c19">Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®) - PDQ Cancer Informat...</a><div class="ralinkpop offscreen_noflow">Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=4" href="/portal/utils/pageresolver.fcgi?recordid=67c959faa68b6b5afc96ab8e">Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) - PDQ Cancer Info...</a><div class="ralinkpop offscreen_noflow">Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=5" href="/portal/utils/pageresolver.fcgi?recordid=67c959eda68b6b5afc963e0b">Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®) - PDQ Ca...</a><div class="ralinkpop offscreen_noflow">Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
|
|
|
|
<!-- Custom content below discovery portlets -->
|
|
<div class="col7">
|
|
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
<!-- Custom content after all -->
|
|
<div class="col8">
|
|
|
|
</div>
|
|
<div class="col9">
|
|
|
|
</div>
|
|
|
|
<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
|
|
<script type="text/javascript">
|
|
(function($){
|
|
$('.skiplink').each(function(i, item){
|
|
var href = $($(item).attr('href'));
|
|
href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
|
|
$(item).on('click', function(event){
|
|
event.preventDefault();
|
|
$.scrollTo(href, 0, {
|
|
onAfter: function(){
|
|
href.focus();
|
|
}
|
|
});
|
|
});
|
|
});
|
|
})(jQuery);
|
|
</script>
|
|
</div>
|
|
<div class="bottom">
|
|
|
|
<div id="NCBIFooter_dynamic">
|
|
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
|
<component id="Breadcrumbs" label="helpdesk"/>-->
|
|
|
|
</div>
|
|
|
|
<div class="footer" id="footer">
|
|
<section class="icon-section">
|
|
<div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
|
|
<div class="grid-container container">
|
|
<div class="icon-section_container">
|
|
<a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<defs>
|
|
<style>
|
|
.cls-11 {
|
|
fill: #737373;
|
|
}
|
|
</style>
|
|
</defs>
|
|
<title>Twitter</title>
|
|
<path class="cls-11" d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<title>Facebook</title>
|
|
<path class="cls-11" d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_linkedin" href="https://www.linkedin.com/company/ncbinlm" aria-label="LinkedIn"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<title>LinkedIn</title>
|
|
<path class="cls-11" d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<defs>
|
|
<style>
|
|
.cls-11,
|
|
.cls-12 {
|
|
fill: #737373;
|
|
}
|
|
|
|
.cls-11 {
|
|
fill-rule: evenodd;
|
|
}
|
|
</style>
|
|
</defs>
|
|
<title>GitHub</title>
|
|
<path class="cls-11" d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
|
|
</path>
|
|
<path class="cls-12" d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
|
|
</path>
|
|
<path class="cls-12" d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
|
|
</path>
|
|
<path class="cls-12" d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
|
|
<path class="cls-12" d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
|
|
<svg xmlns="http://www.w3.org/2000/svg" id="Layer_1" data-name="Layer 1" viewBox="0 0 40 40">
|
|
<defs><style>.cls-1{fill:#737373;}</style></defs>
|
|
<title>NCBI Insights Blog</title>
|
|
<path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"></path>
|
|
</svg>
|
|
</a>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
|
|
<section class="container-fluid bg-primary">
|
|
<div class="container pt-5">
|
|
<div class="row mt-3">
|
|
<div class="col-lg-3 col-12">
|
|
<p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
|
|
<ul class="list-inline social_media">
|
|
<li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<style type="text/css">
|
|
.st20 {
|
|
fill: #FFFFFF;
|
|
}
|
|
|
|
.st30 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
</style>
|
|
<title>Twitter</title>
|
|
<g>
|
|
<g>
|
|
<g>
|
|
<path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7 c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116 c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3 c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6 C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
|
|
</g>
|
|
</g>
|
|
<circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
|
|
</g>
|
|
</svg></a></li>
|
|
<li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine" aria-label="Facebook" rel="noopener noreferrer" target="_blank">
|
|
<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<style type="text/css">
|
|
.st10 {
|
|
fill: #FFFFFF;
|
|
}
|
|
|
|
.st110 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
</style>
|
|
<title>Facebook</title>
|
|
<g>
|
|
<g>
|
|
<path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9 v67.5H135v-67.5h21.7L159,99.1z"></path>
|
|
</g>
|
|
</g>
|
|
<circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
|
|
</svg>
|
|
</a></li>
|
|
<li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<title>Youtube</title>
|
|
<style type="text/css">
|
|
.st4 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
|
|
.st5 {
|
|
fill: #FFFFFF;
|
|
}
|
|
</style>
|
|
<circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
|
|
<g transform="translate(0,-952.36218)">
|
|
<path class="st5" d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7 v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
|
|
</g>
|
|
</svg></a></li>
|
|
</ul>
|
|
</div>
|
|
<div class="col-lg-3 col-12">
|
|
<p class="address_footer text-white">National Library of Medicine<br />
|
|
<a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323" class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br />
|
|
Bethesda, MD 20894</a></p>
|
|
</div>
|
|
<div class="col-lg-3 col-12 centered-lg">
|
|
<p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br />
|
|
<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="text-white">FOIA</a><br />
|
|
<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
|
|
</div>
|
|
<div class="col-lg-3 col-12 centered-lg">
|
|
<p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br />
|
|
<a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br />
|
|
<a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
|
|
</div>
|
|
</div>
|
|
<div class="row">
|
|
<div class="col-lg-12 centered-lg">
|
|
<nav class="bottom-links">
|
|
<ul class="mt-3">
|
|
<li>
|
|
<a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.nih.gov/">NIH</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.hhs.gov/">HHS</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.usa.gov/">USA.gov</a>
|
|
</li>
|
|
</ul>
|
|
</nav>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<!--/.page-->
|
|
</div>
|
|
<!--/.wrap-->
|
|
</div><!-- /.twelve_col -->
|
|
</div>
|
|
<!-- /.grid -->
|
|
|
|
<span class="PAFAppResources"></span>
|
|
|
|
<!-- BESelector tab -->
|
|
|
|
|
|
|
|
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK65870&ncbi_domain=pdqcis&ncbi_report=record&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK65870.4/&ncbi_pagename=Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf&ncbi_bookparttype=chapter&ncbi_app=bookshelf" /></noscript>
|
|
|
|
|
|
<!-- usually for JS scripts at page bottom -->
|
|
<!--<component id="PageFixtures" label="styles"></component>-->
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4209313/4212053/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
|
|
</html> |